Current approaches and perspectives in the therapy of medullary thyroid carcinoma

Cancer

Volumn 91, Issue 9, 2001, Pages 1797-1808

  Vitale, Giovanni ^a   Caraglia, Michele ^b   Ciccarelli, Antonio ^c   Lupoli, Gelsy ^b   Abbruzzese, Alberto ^c   Tagliaferri, Pierosandro ^b   Lupoli, Giovanni ^a,d  

^a UNIVERSITY OF NAPLES FEDERICO II   (Italy)

^b SECOND UNIVERSITY OF NAPLES   (Italy)

^c UNIVERSITY MAGNA GRAECIA OF CATANZARO   (Italy)

^d Department of Molecular and Clinical Endocrinology and Oncology ^*  (Italy)

Author keywords

Chemotherapy; Interferon; Medullary thyroid carcinoma; Somatostatin analog; Surgery; Therapy

Indexed keywords

ALPHA INTERFERON; ANGIOPEPTIN; BLEOMYCIN; CISPLATIN; CYCLOPHOSPHAMIDE; DACARBAZINE; DOXORUBICIN; FLUOROURACIL; LEVOTHYROXINE; MITOXANTRONE; OCTREOTIDE; SOMATOSTATIN DERIVATIVE; STREPTOZOCIN; TAMOXIFEN; VINCRISTINE; VINDESINE;

ARTICLE; GENETIC COUNSELING; HUMAN; MULTIMODALITY CANCER THERAPY; PRIORITY JOURNAL; SURGICAL TECHNIQUE; THYROID MEDULLARY CARCINOMA; THYROIDECTOMY; TREATMENT INDICATION; TREATMENT OUTCOME; TREATMENT PLANNING;

ANTINEOPLASTIC AGENTS; CARCINOMA, MEDULLARY; DNA, NEOPLASM; DRUG THERAPY; GENETIC COUNSELING; HUMANS; SOMATOSTATIN; THYROID NEOPLASMS;

EID: 0035340632     PISSN: 0008543X     EISSN: None     Source Type: Journal    
DOI: 10.1002/1097-0142(20010501)91:9<1797::AID-CNCR1199>3.0.CO;2-P     Document Type: Article

References (108)

1. Regulatory peptides and other neuroendocrine markers in medullary carcinoma of the thyroid
2. Human medullary thyroid carcinoma in tissue culture: Secretion of calcitonin and carcinoembryonic antigen
3. A GTG to ATG novel point mutation at codon 804 in exon 14 of the RET proto-oncogene in two families affected by familial medullary thyroid carcinoma
4. Germ line mutation analysis in families with multiple endocrine neoplasia type 2A or familial medullary thyroid carcinoma
5. Mapping the inherited defects associated with multiple endocrine neoplasia type 2A, multiple endocrine neoplasia type 2B, and familial medullary thyroid carcinoma to chromosome 10 by linkage analysis
6. Mutations in the RET proto-oncogene are associated with MEN 2A and FMTC
7. RET mutations in exons 13 and 14 of FMTC patients
8. Distinct biological properties of two RET isoforms activated by MEN 2A and MEN 2B mutations
9. The relationship between specific RET proto-oncogene mutations and disease phenotype in multiple endocrine neoplasia type 2. International RET mutation consortium analysis
10. Germ-line mutations of the RET proto-oncogene in multiple endocrine neoplasia type 2A
11. A mutation in the RET proto-oncogene associated with multiple endocrine neoplasia type 2B and sporadic medullary thyroid carcinoma
12. Single missense mutation in the tyrosine kinase catalytic domain of the RET protooncogene is associated with multiple endocrine neoplasia type 2B
13. Medullary carcinoma of thyroid. Biologic behavior of the sporadic and familial neoplasm
14. Medullary thyroid carcinoma: Clinical features and long-term follow-up of seventy-eight patients treated between 1969-1986
15. Screening for adrenal medullary disease in patients with medullary thyroid carcinoma
16. Dilemmas in the early diagnosis and treatment of multiple endocrine adenomatosis, type 2
17. Surgical management of the adrenal glands in the multiple endocrine neoplasia type II syndrome
18. Management of pheochromocytomas in patients with multiple endocrine neoplasia type 2 syndromes
19. Unilateral versus bilateral adrenalectomy in multiple endocrine neoplasia IIA
20. Early diagnosis of and surgical strategy for adrenal medullary disease in MEN II gene carriers
21. Phaeochromocytoma in multiple endocrine neoplasia type 2A; survey of 100 cases
22. Management of individual tumor syndromes. Medullary thyroid carcinoma and hyperparathyroidism
23. Medullary thyroid cancer
24. The extent of surgery for thyroid medullary cancer
25. The clinical outcome of prospective screening for multiple endocrine neoplasia type 2A. An 18 year experience
26. Clinical characteristics distinguishing hereditary from sporadic medullary thyroid carcinoma. Treatment implications
27. Patterns of nodal metastases in palpable medullary thyroid carcinoma
28. Compartment-oriented microdissection of regional lymph nodes in medullary thyroid carcinoma
29. The value of lymph node dissection in hereditary medullary thyroid carcinoma: A retrospective, European, multicentre study
30. Frequency and significance of cervicomediastinal lymph node metastases in medullary thyroid carcinoma: Results of a compartment-oriented microdissection method
31. Impact of therapeutic regional lymph node dissection for medullary carcinoma of the thyroid gland
32. Surgical strategy for the treatment of medullary thyroid carcinoma
33. Surgical management of hyperparathyroidism in patients with multiple endocrine neoplasia type 2A
34. Improved results of cervical reoperation for medullary thyroid carcinoma
35. GDNF-induced activation of the ret protein tyrosine kinase is mediated by GDNFR-alpha, a novel receptor for GDNF
36. Characterization of a multicomponent receptor for GDNF
37. Activation of RET as a dominant transforming gene by germline mutations of MEN 2A and MEN 2B
38. Medullary thyroid carcinoma
39. Current diagnosis and management of medullary thyroid carcinoma
40. Germline and somatic mutations of the RET proto-oncogene in apparently sporadic medullary thyroid carcinomas
41. The RET proto-oncogene in medullary and papillary thyroid carcinoma. Molecular features, pathophysiology and clinical implications
42. Omeprazole: Calcitonin stimulation test for the diagnosis follow-up and family screening in medullary thyroid carcinoma
43. A comparison of calcium pentagastrin and TRH test in screening for medullary carcinoma of the thyroid in MEN IIA
44. Predictive DNA testing and prophylactic thyroidectomy in patients at risk for multiple endocrine neoplasia type 2A
45. Clinical screening as compared with DNA analysis in families with multiple endocrine neoplasia type 2A
46. Multiple endocrine neoplasia type 2: Recent progress in diagnosis and management
47. Seventeen-year-long follow-up of a family affected by type 2A multiple endocrine neoplasia (MEN 2A)
48. Early treatment of hereditary medullary thyroid carcinoma after attribution of multiple endocrine neoplasia type 2 gene carrier status by screening for ret gene mutations
49. Presymptomatic DNA screening in families with multiple endocrine neoplasia type 2 and familial medullary thyroid carcinoma
50. Prophylactic thyroidectomy in 75 children and adolescents with hereditary medullary thyroid carcinoma: German and Austrian experience
51. Medullary thyroid carcinoma: Clinical characteristics, treatment, prognostic factors, and a comparison of staging systems
52. Advances and controversies in the diagnosis and management of medullary thyroid carcinoma
53. Relationship of carcinoembryonic antigen and calcitonin to tumor virulence in medullary thyroid carcinoma
54. The value of calcitonin and carcinoembryonic antigen in the treatment and management of non familial medullary thyroid cancer
55. Diagnostic and prognostic values of carcinoembryonic antigen in medullary thyroid carcinoma of the thyroid
56. (131I)meta-iodobenzylguanidine scintigraphy and selective venous catheterization after thyroidectomy for medullary thyroid carcinoma
57. 111In-pentetreotide scintigraphy in the post-thyroidectomy follow-up of patients with medullary thyroid carcinoma
58. Medullary thyroid carcinoma
59. Laparoscopic detection of hepatic metastases in patients with residual or recurrent medullary thyroid cancer
60. Reoperation in the treatment of asymptomatic metastasizing medullary thyroid carcinoma
61. Microsurgical neck dissection for mestasizing medullary thyroid carcinoma
62. Long-term course of patients with persistent hypercalcitoninemia after apparent curative primary surgery for medullary thyroid carcinoma
63. Medullary thyroid carcinoma: Prognosis of familial versus non familial disease and the role of radiotherapy
64. Medullary thyroid cancer: Analyses of survival and prognostic factors and role of radiation therapy in local control
65. Thyroid carcinoma
66. Radioactive iodine in the treatment of medullary carcinoma of the thyroid
67. The role of 131-I metaiodobenzylguanidine in the treatment of medullary thyroid carcinoma: Results in five cases
68. Indium-111 activity concentration in tissue samples after intravenous injection of indium-111-DTPA-D-Phe-1-octreotide
69. Therapy of neuroendocrine tumors with radiolabeled MIBG and somatostatin analogue
70. Radioimmunotherapy of medullary thyroid cancer with iodine-131-labeled anti-CEA antibodies
71. Targeting and initial radioimmunotherapy of medullary thyroid carcinoma with 131I-labeled monoclonal antibodies to carcinoembryonic antigen
72. Chemotherapy of thyroid carcinoma
73. A randomized trial of doxorubicin versus doxorubicin plus cisplatin in patients with advanced thyroid carcinoma
74. Medullary carcinoma of the thyroid treated by low-dose adriamycin
75. Combined chemotherapy with bleomycin, adriamycin and platinum in advanced thyroid cancer
76. Combination chemotherapy of advanced medullary and differentiated thyroid cancer. Phase II study
77. Treatment of advanced medullary thyroid carcinoma with a combination of cyclophosphamide, vincristine, and dacarbazine
78. Chemotherapy with dacarbazine and 5-fluorouracil in advanced medullary thyroid cancer
79. Metastatic medullary thyroid carcinoma. Complete response to combination chemotherapy with dacarbazine and 5-fluorouracil
80. Treatment of advanced medullary thyroid cancer with an alternating combination of 5 FU-streptozocin and 5 FU-dacarbazine
81. Mitoxantrone in metastatic apudomas: A phase II study of the EORTC Gastro-Intestinal Cancer Co-operative Group
82. Tamoxifen failure in medullary thyroid carcinoma
83. Intrinsic drug resistance in a human medullary thyroid carcinoma cell line: Association with overexpression of mdr1 gene and low proliferation fraction
84. Ex-pression of the MDR1 gene in five human cell lines of medullary thyroid cancer and reversion of the resistance to doxorubicine by ciclosporin A and verapamil
85. Effect of PSC 833 on the efficacy of doxorubicin in vitro in a medullary thyroid carcinoma cell line
86. Quality of life research in oncology
87. Methodologic issues in assessing the quality of life of cancer patients
88. The role of somatostatin and its analogues in the diagnosis and treatment of tumors
89. Somatostatin 1
90. Somatostatin 2
91. Somatostatin and somatostatin analogues: Pharmacokinetics and pharmacodynamic effects
92. From somatostatin to sandostatin: Pharmacodynamics and pharmacokinetics
93. Long-term treatment of metastatic medullary thyroid carcinoma with the somatostatin analogue octreotide
94. Results of long term continuous subcutaneous octreotide administration in 14 patients with medullary thyroid carcinoma
95. The use of octreotide in the treatment of medullary thyroid carcinoma
96. α-interferon potentiates epidermal growth factor receptor-mediated effects on human epidermoid carcinoma KB cells
97. Therapy of metastatic carcinoid tumor and the malignant carcinoid syndrome with recombinant leukocyte α-interferon
98. Inhibitory effect of interferon on cellular DNA synthesis: Modulation by pure mitogenic factors
99. Alphainterferon down-regulates epidermal growth factor receptors on renal carcinoma cells: Relation to cellular responsiveness to the antiproliferative action of alpha-interferon
100. Response of medullary thyroid cancer to low dose alpha-interferon-2a
101. Treatment of metastatic carcinoids and other neuroendocrine tumors with recombinant interferonalpha-2a
102. Treatment of advanced medullary thyroid carcinoma with a combination of recombinant interferon α-2b and octreotide
103. Slow release lanreotide in combination with interferon-α2b in the treatment of symptomatic advanced medullary thyroid carcinoma
104. Interleukin-2 and interleukin-4 display potent antitumour activity on rat medullary thyroid carcinoma cells
105. Immune response against medullary thyroid carcinoma (MTC) induced by parental and/or interleukin-2-secreting MTC cells in a rat model of human familial medullary thyroid carcinoma
106. Immunotherapy for medullary thyroid carcinoma by a replication-defective adenovirus transducing murine interleukin-2
107. Genetic immunotherapy for medullary thyroid carcinoma destruction of tumors in mice by in vivo delivery of adenoviral vector transducing the murine interleukin-2 gene
108. Surgical management and follow-up of medullary thyroid carcinoma